Logo image of GBIO

GENERATION BIO CO (GBIO) Stock Overview

NASDAQ:GBIO - US37148K1007 - Common Stock

5.95 USD
+0.17 (+2.94%)
Last: 9/5/2025, 12:50:00 PM

GBIO Key Statistics, Chart & Performance

Key Statistics
52 Week High29.1
52 Week Low3
Market Cap40.10M
Shares6.74M
Float5.77M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-8.75
PEN/A
Fwd PEN/A
Earnings (Next)11-04 2025-11-04/amc
IPO06-12 2020-06-12
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


GBIO short term performance overview.The bars show the price performance of GBIO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30

GBIO long term performance overview.The bars show the price performance of GBIO in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of GBIO is 5.95 USD. In the past month the price increased by 35.05%. In the past year, price decreased by -73.49%.

GENERATION BIO CO / GBIO Daily stock chart

GBIO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 20 374.09B
AMGN AMGEN INC 12.94 151.98B
GILD GILEAD SCIENCES INC 14.84 142.57B
VRTX VERTEX PHARMACEUTICALS INC 23.3 101.21B
REGN REGENERON PHARMACEUTICALS 12.51 60.53B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.44B
ARGX ARGENX SE - ADR 80.86 45.87B
ONC BEONE MEDICINES LTD-ADR 6.81 40.16B
INSM INSMED INC N/A 30.28B
BNTX BIONTECH SE-ADR N/A 26.95B
NTRA NATERA INC N/A 22.89B
BIIB BIOGEN INC 8.89 20.87B

About GBIO

Company Profile

GBIO logo image Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 115 full-time employees. The company went IPO on 2020-06-12. The firm is engaged in developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. The company focuses on autoimmune targets that have been undruggable or poorly drugged selectively in T cells. Its proprietary cell-targeted lipid nanoparticle (ctLNP) technology enables selective access to T cells and precise target inhibition by siRNA to selectively modulate T cells, blocking autoimmune tissue damage while sparing the broader immune system. Its proprietary stealth technology prevents its LNP from interacting with serum-binding proteins and reduces clearance by the liver and spleen to less than 1%, enabling potency and selectivity. Its selective delivery allows it to inhibit targets in T cells while sparing critical function in other cell types.

Company Info

GENERATION BIO CO

301 Binney Street

Cambridge MASSACHUSETTS 02142 US

CEO: Geoff McDonough

Employees: 115

GBIO Company Website

GBIO Investor Relations

Phone: 18575295908

GENERATION BIO CO / GBIO FAQ

What is the stock price of GENERATION BIO CO today?

The current stock price of GBIO is 5.95 USD. The price increased by 2.94% in the last trading session.


What is the ticker symbol for GENERATION BIO CO stock?

The exchange symbol of GENERATION BIO CO is GBIO and it is listed on the Nasdaq exchange.


On which exchange is GBIO stock listed?

GBIO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for GENERATION BIO CO stock?

12 analysts have analysed GBIO and the average price target is 27.29 USD. This implies a price increase of 358.57% is expected in the next year compared to the current price of 5.95. Check the GENERATION BIO CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GENERATION BIO CO worth?

GENERATION BIO CO (GBIO) has a market capitalization of 40.10M USD. This makes GBIO a Nano Cap stock.


How many employees does GENERATION BIO CO have?

GENERATION BIO CO (GBIO) currently has 115 employees.


What are the support and resistance levels for GENERATION BIO CO (GBIO) stock?

GENERATION BIO CO (GBIO) has a support level at 4.63 and a resistance level at 6.12. Check the full technical report for a detailed analysis of GBIO support and resistance levels.


Is GENERATION BIO CO (GBIO) expected to grow?

The Revenue of GENERATION BIO CO (GBIO) is expected to decline by -33.06% in the next year. Check the estimates tab for more information on the GBIO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy GENERATION BIO CO (GBIO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GENERATION BIO CO (GBIO) stock pay dividends?

GBIO does not pay a dividend.


When does GENERATION BIO CO (GBIO) report earnings?

GENERATION BIO CO (GBIO) will report earnings on 2025-11-04, after the market close.


What is the Price/Earnings (PE) ratio of GENERATION BIO CO (GBIO)?

GENERATION BIO CO (GBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-8.75).


GBIO Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to GBIO. When comparing the yearly performance of all stocks, GBIO is a bad performer in the overall market: 89.7% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

GBIO Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to GBIO. While GBIO seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GBIO Financial Highlights

Over the last trailing twelve months GBIO reported a non-GAAP Earnings per Share(EPS) of -8.75. The EPS decreased by -266.11% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -40.36%
ROE -133.86%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-906.45%
Sales Q2Q%-81.3%
EPS 1Y (TTM)-266.11%
Revenue 1Y (TTM)61.1%

GBIO Forecast & Estimates

12 analysts have analysed GBIO and the average price target is 27.29 USD. This implies a price increase of 358.57% is expected in the next year compared to the current price of 5.95.

For the next year, analysts expect an EPS growth of -141.65% and a revenue growth -33.06% for GBIO


Analysts
Analysts81.67
Price Target27.29 (358.66%)
EPS Next Y-141.65%
Revenue Next Year-33.06%

GBIO Ownership

Ownership
Inst Owners71.78%
Ins Owners2.87%
Short Float %N/A
Short Ratio0.25